Xiaohua Wu1, Liz Y Han, Xin Xu, Ziting Li. 1. Department of Gynecologic Oncology, Cancer Hospital of Fudan University, 270 Dong-an Road, Shanghai 200032, China. docwuxh@hotmail.com
Abstract
BACKGROUND: Composing of less than 1% of all ovarian cancers, immature teratoma is a malignancy that mainly affects the young. Although standard treatment protocol for primary disease has improved over the past decades, the role of secondary cytoreduction in the setting of recurrence remains controversial. CASE: A 20-year-old Chinese female presented with recurrent immature teratoma at the level of the aortic bifurcation. Patient was status post a right salpingo-oophorectomy at time of her initial diagnosis 8 years ago, and subsequent exploratory laparotomies and chemotherapy when recurrence that developed at the before-mentioned site. She ultimately underwent a radical cytoreduction with en-block excision of the aortic mass and simultaneous artificial aortic bifurcation graft. CONCLUSION: There may be a beneficial role of radical secondary cytoreduction in the setting of recurrent immature teratoma.
BACKGROUND: Composing of less than 1% of all ovarian cancers, immature teratoma is a malignancy that mainly affects the young. Although standard treatment protocol for primary disease has improved over the past decades, the role of secondary cytoreduction in the setting of recurrence remains controversial. CASE: A 20-year-old Chinese female presented with recurrent immature teratoma at the level of the aortic bifurcation. Patient was status post a right salpingo-oophorectomy at time of her initial diagnosis 8 years ago, and subsequent exploratory laparotomies and chemotherapy when recurrence that developed at the before-mentioned site. She ultimately underwent a radical cytoreduction with en-block excision of the aortic mass and simultaneous artificial aortic bifurcation graft. CONCLUSION: There may be a beneficial role of radical secondary cytoreduction in the setting of recurrent immature teratoma.
Authors: S Shanmughapriya; G SenthilKumar; K Balakrishnan; N Vasanthi; K Vinodhini; K Natarajaseenivasan Journal: BMC Cancer Date: 2011-06-03 Impact factor: 4.430